Advances in Aptamers-Based Applications in Breast Cancer : Drug Delivery, Therapeutics, and Diagnostics
Aptamers are synthetic single-stranded oligonucleotides (such as RNA and DNA) evolved in vitro using Systematic Evolution of Ligands through Exponential enrichment (SELEX) techniques. Aptamers are evolved to have high affinity and specificity to targets; hence, they have a great potential for use in therapeutics as delivery agents and/or in treatment strategies. Aptamers can be chemically synthesized and modified in a cost-effective manner and are easy to hybridize to a variety of nano-particles and other agents which has paved a way for targeted therapy and diagnostics applications such as in breast tumors. In this review, we systematically explain different aptamer adoption approaches to therapeutic or diagnostic uses when addressing breast tumors. We summarize the current therapeutic techniques to address breast tumors including aptamer-base approaches. We discuss the next aptamer-based therapeutic and diagnostic approaches targeting breast tumors. Finally, we provide a perspective on the future of aptamer-based sensors for breast therapeutics and diagnostics. In this section, the therapeutic applications of aptamers will be discussed for the targeting therapy of breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 23(2022), 22 vom: 21. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gholikhani, Tooba [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aptamer |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 13.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms232214475 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349439044 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349439044 | ||
| 003 | DE-627 | ||
| 005 | 20231226042627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms232214475 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349439044 | ||
| 035 | |a (NLM)36430951 | ||
| 035 | |a (PII)14475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gholikhani, Tooba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances in Aptamers-Based Applications in Breast Cancer |b Drug Delivery, Therapeutics, and Diagnostics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 13.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aptamers are synthetic single-stranded oligonucleotides (such as RNA and DNA) evolved in vitro using Systematic Evolution of Ligands through Exponential enrichment (SELEX) techniques. Aptamers are evolved to have high affinity and specificity to targets; hence, they have a great potential for use in therapeutics as delivery agents and/or in treatment strategies. Aptamers can be chemically synthesized and modified in a cost-effective manner and are easy to hybridize to a variety of nano-particles and other agents which has paved a way for targeted therapy and diagnostics applications such as in breast tumors. In this review, we systematically explain different aptamer adoption approaches to therapeutic or diagnostic uses when addressing breast tumors. We summarize the current therapeutic techniques to address breast tumors including aptamer-base approaches. We discuss the next aptamer-based therapeutic and diagnostic approaches targeting breast tumors. Finally, we provide a perspective on the future of aptamer-based sensors for breast therapeutics and diagnostics. In this section, the therapeutic applications of aptamers will be discussed for the targeting therapy of breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a aptamer | |
| 650 | 4 | |a cancer diagnostics | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a drug delivery | |
| 650 | 7 | |a Aptamers, Nucleotide |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 700 | 1 | |a Kumar, Shalen |e verfasserin |4 aut | |
| 700 | 1 | |a Valizadeh, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdinloo, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Adibkia, Khosro |e verfasserin |4 aut | |
| 700 | 1 | |a Zakeri-Milani, Parvin |e verfasserin |4 aut | |
| 700 | 1 | |a Barzegar-Jalali, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, Balam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 23(2022), 22 vom: 21. Nov. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:22 |g day:21 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms232214475 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 22 |b 21 |c 11 | ||